Impairment of IFN-α production capacity in patients with hepatitis C virus and the risk of the development of hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 46, 2005, Pages 7330-7334

  Uno, Kazuko ^a   Suginoshita, Yoshiki ^b   Kakimi, Kazuhiro ^b   Moriyasu, Fuminori ^b   Hirosaki, Mayumi ^c   Shirakawa, Taro ^c   Kishida, Tsunataro ^a  

^a Louis Pasteur Center for Medical Research   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; IFN production capacity

Indexed keywords

ALPHA INTERFERON;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE DURATION; EARLY DIAGNOSIS; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT MONITORING; SENDAI VIRUS;

EID: 31344446884     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i46.7330     Document Type: Article

References (28)

1. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-675
2. Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26: 21S-28S
3. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969-974
4. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-938
5. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127: S17-2
6. Huo TI, Lui WY, Huang YH, Chau GY, Wu JC, Lee PC, Chang FY, Lee SD. Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. Am J Gastroenterol 2003; 98: 2293-2298
7. Nakajima T, Mizushima N, Kanai K. Relationship between natural killer activity and development of hepatocellular carcinoma in patients with cirrhosis of the liver. Jpn J Clin Oncol 1987; 17: 327-332
8. Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, Sasaki Y, Kasahara A, Hori M. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999; 162: 5584-5591
9. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Suzuki T, Miyagi T, Hayashi N. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol 2003; 171: 5423-5429
10. Jinushi M, Takehara T, Kanto T, Tatsumi T, Groh V, Spies T, Miyagi T, Suzuki T, Sasaki Y, Hayashi N. Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Immunol 2003; 170: 1249-1256
11. Jinushi M, Takehara T, Tatsumi T, Kanto T, Miyagi T, Suzuki T, Kanazawa Y, Hiramatsu N, Hayashi N. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 2004; 173: 6072-6081
12. Uno K, Nakano K, Maruo N, Onodera H, Mata H, Kurosu I, Akatani K, Ikegami N, Kishi A, Yasuda Y, Tanaka K, Setoguchi J, Kondo M, Muramatsu S, Kishida T. Determination of interferon-alpha-producing capacity in whole blood cultures from patients with various diseases and from healthy persons. J Interferon Cytokine Res 1996; 16: 911-918
13. Shirakawa K, Muso E, Nogaki F, Maeda M, Kawamura T, Ono T, Yoshimoto M, Uno K, Kishida T, Sasayama S. Correlation between the severity of clinicopathological parameters and whole blood interferon-alpha production capacity in active phase IgA nephropathy patients. Nephron 2002; 90: 24-30
14. Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, Ishibashi H, Yamada G, Yokosuka O, Shiratori Y, Omata M. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425-430
15. Mufti G, List AF, Gore SD, Ho AY. Myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Program) 2003: 176-199
16. Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004; 45: 1311-1318
17. Gobl AE, Funa K, Alm GV. Different induction patterns of mRNA for IFN-alpha and -beta in human mononuclear leukocytes after in vitro stimulation with herpes simplex virus-infected fibroblasts and Sendai virus. J Immunol 1988; 140: 3605-3609
18. Gary-Gouy H, Lebon P, Dalloul AH. Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines. J Interferon Cytokine Res 2002; 22: 653-659
19. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 119-134
20. Gresser I, Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 2002; 13: 111-118
21. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148
22. Reid LM, Minato N, Gresser I, Holland J, Kadish A, Bloom BR. Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice. Proc Natl Acad Sci USA 1981; 78: 1171-1175
23. Gresser I, Maury C, Kaido T, Bandu MT, Tovey MG, Maunoury MT, Fantuzzi L, Gessani S, Greco G, Belardelli F. The essential role of endogenous IFN alpha/beta in the anti-metastatic action of sensitized T lymphocytes in mice injected with Friend erythroleukemia cells. Int J Cancer 1995; 63: 726-731
24. Ramani P, Balkwill FR. Action of recombinant alpha interferon against experimental and spontaneous metastases in a murine model. Int J Cancer 1989; 43: 140-146
25. Ferrantini M, Giovarelli M, Modesti A, Musiani P, Modica A, Venditti M, Peretti E, Lollini PL, Nanni P, Forni G. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J Immunol 1994; 153: 4604-4615
26. Kaido TJ, Maury C, Gresser I. Host CD4+ T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases. Cancer Res 1995; 55: 6133-6139
27. Uno K, Shimizu S, Inaba K, Kitaura M, Nakahira K, Kato T, Yamaguchi Y, Muramatsu S. Effect of recombinant human interferon-alpha A/D on in vivo murine tumor cell growth. Cancer Res 1988; 48: 2366-2371
28. Akahoshi M, Ishihara M, Remus N, Uno K, Miyake K, Hirota T, Nakashima K, Matsuda A, Kanda M, Enomoto T, Ohno S, Nakashima H, Casanova JL, Hopkin JM, Tamari M, Mao XQ, Shirakawa T. Association between IFNA genotype and the risk of sarcoidosis. Hum Genet 2004; 114: 503-509